Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces year end Trading Update Good progress across all key projects in 2022 Brighton, United Kingdom – 22 December 2022 […]
Wednesday December 7, 2022
XF-73 Nasal final Phase 3 development plans
Destiny Pharma plc (“Destiny Pharma” or “the Company”) US FDA/CDC workshop highlights the need for new approaches for the prevention of hospital-acquired infections · Particular support for decolonisation of pathogens […]